PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,324 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $75.44, for a total transaction of $175,322.56. Following the completion of the sale, the insider now directly owns 8,876 shares in the company, valued at $669,605.44. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.
Andrew Okun also recently made the following trade(s):
- On Monday, February 5th, Andrew Okun sold 2,273 shares of PerkinElmer stock. The shares were sold at an average price of $77.86, for a total transaction of $176,975.78.
- On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The shares were sold at an average price of $72.00, for a total transaction of $912,960.00.
Shares of PerkinElmer, Inc. (NYSE:PKI) opened at $72.83 on Friday. PerkinElmer, Inc. has a 12 month low of $53.63 and a 12 month high of $84.49. The stock has a market cap of $8,027.69, a PE ratio of 24.94, a price-to-earnings-growth ratio of 1.68 and a beta of 0.76. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72.
The company also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Shareholders of record on Friday, April 13th will be paid a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, April 12th. This represents a $0.28 annualized dividend and a dividend yield of 0.38%. PerkinElmer’s dividend payout ratio is currently 10.61%.
Institutional investors have recently added to or reduced their stakes in the business. American Century Companies Inc. acquired a new stake in shares of PerkinElmer in the fourth quarter worth approximately $61,260,000. Koch Industries Inc. acquired a new stake in shares of PerkinElmer in the second quarter worth approximately $364,000. Assenagon Asset Management S.A. acquired a new stake in shares of PerkinElmer in the third quarter worth approximately $23,168,000. Robecosam AG boosted its position in shares of PerkinElmer by 165.7% in the third quarter. Robecosam AG now owns 477,167 shares of the medical research company’s stock worth $32,610,000 after acquiring an additional 297,595 shares during the last quarter. Finally, BlackRock Inc. boosted its position in shares of PerkinElmer by 3.2% in the fourth quarter. BlackRock Inc. now owns 6,260,111 shares of the medical research company’s stock worth $457,740,000 after acquiring an additional 195,851 shares during the last quarter. 90.98% of the stock is currently owned by institutional investors.
A number of equities research analysts recently commented on PKI shares. Robert W. Baird increased their price objective on shares of PerkinElmer from $75.00 to $78.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research note on Monday, January 8th. Morgan Stanley increased their price objective on shares of PerkinElmer from $77.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, November 3rd. Jefferies Group reissued a “hold” rating and issued a $70.00 price objective on shares of PerkinElmer in a research note on Friday, October 20th. Finally, Cowen reissued a “hold” rating and issued a $84.00 price objective on shares of PerkinElmer in a research note on Friday, January 26th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $76.85.
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.